The prevalence of vascular dementia in europe: Facts and fragments from 1980–1990 studies

Rocca, Walter A.; Hofman, Albert; Brayne, Carol; Breteler, Monique M.B.; Clarke, Michael; Copeland, J. R. M.; Dartiques, J.-F.; Engedal, Knut; Hagnell, Olle; Heeren, Thea J.; Jonker, Cees; Lindesay, James; Lobò, Antonio; Mann, Anthony; Mölsä, P.K.; Morgan, Kevin; O'Connor, Daniel William; Droux, Arnaldo da Silva; Sulkava, Raimo; Kay, D. W. K.; Amaducci, L.

doi:10.1002/ana.410300611

Cited by 164 publications

(81 citation statements)

References 28 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other causes of dementia include vascular dementia (VAD), dementia with Lewy bodies (DLB) and frontotemporal or frontal lobe dementia (FLD). [3][4][5] Dementia in AD is a primary degenerative cerebral disease of unknown aetiology with characteristic neuropathological and neurochemical features. The disorder is usually insidious in onset and it is difficult to set a clear threshold on the continuum between normality and dementia, but this is often defined when cognitive impairment is sufficient to interfere with normal social functioning.…”

Section: Description Of Underlying Health Problemmentioning

confidence: 99%

See 1 more Smart Citation

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

Loveman

Green²,

Kirby³

et al. 2006

Health Technol Assess

165

114

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAThe clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA Programme commissions research only on topics where it has identified key ...

show abstract

Section: Description Of Underlying Health Problemmentioning

confidence: 99%

“…3,5,9,10 These ranges reflect diagnostic difficulties, the use of different diagnostic criteria and the high frequency of mixed pathology. 4,11,12 Over 30% of patients with AD have been found to have vascular pathology on post mortem. 13,14 …”

Section: Prevalence and Incidence Prevalencementioning

confidence: 99%

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

Loveman

Green²,

Kirby³

et al. 2006

Health Technol Assess

165

114

View full text Add to dashboard Cite

show abstract

“…Epidemiological data on vascular dementia are, however, both sparse and of poor reliability (Rocca et al, 1991). Rigorous pathological confirmation is rarely available.…”

Section: Cerebrovascular and Cardiovascular Diseasementioning

confidence: 99%

Susceptibility Genetics in the Etiopathogenesis of Alzheimer's Disease: Role for Potential Confounding Factors

Harrington

Roth

1997

Int. Psychogeriatr.

View full text Add to dashboard Cite

show abstract

“…surveys and clinicopathological studies have established that cerebrovascular disease is one of the three main causes of dementia (Tomlinson et al, 1970;Rocca et al, 1991;OU et al, 1995). A variety of pathological processes may be involved, such as multiple cortical or lacunar infarcts and white matter ischaemia (Amar & Wilcock, 1996).…”

mentioning

confidence: 99%

Management of cognitive impairment of vascular origin

Dennis

Boyle

1998

Psychiatr. bull.

View full text Add to dashboard Cite

A postal questionnaire concerning the management of cognitive impairment of vascular origin was completed by 88 psychogeriatricians and 100 geriatricians. Aspirin was considered an important part of management, and clinically indicated with: a history, or clinical signs of stroke; computerised tomography (CT) scan changes suggestive of cerebrovascular disease; and atrial fibrillation. Advanced dementia was seen as a contraindication for treatment. Eighty per cent of responders indicated they would institute antihypertensive therapy in an elderly patient with a history of raised blood pressure and cognitive impairment. The median lower limit of systolic blood pressure requiring treatment was loOmmHg, with a treatment target blood pressure of ISOmmHg.

show abstract

The prevalence of vascular dementia in europe: Facts and fragments from 1980–1990 studies

Cited by 164 publications

References 28 publications

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

Susceptibility Genetics in the Etiopathogenesis of Alzheimer's Disease: Role for Potential Confounding Factors

Management of cognitive impairment of vascular origin

Contact Info

Product

Resources

About